Alligator Bioscience
Scheelevägen 19 A
Lund
223 70
Tel: 46-0-46-286-4280
Fax: 46-0-46-286-4290
Website: http://www.alligatorbioscience.com/
Email: info@alligatorbioscience.com
122 articles about Alligator Bioscience
-
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
3/7/2024
Alligator Bioscience AB and Aptevo Therapeutics today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4.
-
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
2/13/2023
Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of the first patient in the companies' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
9/19/2022
Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
4/1/2022
Alligator Bioscience announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB targeting drug candidate, ATOR-1017.
-
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
3/23/2022
Alligator Bioscience announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab.
-
Alligator Bioscience AB: Year End report January-December 2021
2/11/2022
During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs.
-
Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer
2/1/2022
Alligator Bioscience Alligator Bioscience, announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer.
-
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
1/19/2022
Alligator Bioscience announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OPTIMIZE-1 study with the University of Pennsylvania's Pancreatic Cancer Research Center.
-
Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
1/18/2022
Alligator Bioscience announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset, mitazalimab.
-
Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data
12/16/2021
Alligator Bioscience announced an update on the on-going clinical Phase I trial with the 4-1BB drug candidate ATOR-1017, which is developed as a tumor-directed therapy for metastatic cancer.
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
12/15/2021
Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting bispecific antibodies.
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
12/15/2021
Alligator Bioscience AB today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies.
-
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
11/11/2021
Alligator Bioscience AB and Aptevo Therapeutics announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society of Immunotherapy Cancer's 36th Annual Meeting, taking place virtually and in-person November 12- 14, 2021 in Washington D.C.
-
Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam
11/8/2021
First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer
-
Alligator Bioscience AB: Interim report January-September 2021
10/21/2021
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer.
-
Notice of extraordinary general meeting in Alligator Bioscience AB
10/7/2021
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 8 November 2021.
-
Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
9/2/2021
Alligator Bioscience AB and Scandion Oncology A/S, announced the conclusion of their collaboration with a very positive outcome.
-
Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
9/2/2021
Alligator Bioscience AB announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity.